NEUROGESX INC COM STK USD0.001 (NGSX)

0.01
0.00 28.57
OTC
Prev Close 0.01
Open 0.01
Day Low/High 0.00 / 0.01
52 Wk Low/High 0.00 / 0.01
Volume 280.12K
Exchange OTC
Shares Outstanding 33.33M
Market Cap 233.30K
Div & Yield N.A. (N.A)

Latest News

NeurogesX's CEO Discusses Q2 2012 Results - Earnings Call Transcript

NeurogesX's CEO Discusses Q2 2012 Results - Earnings Call Transcript

NeurogesX's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Insiders Trading TXI, P, NGSX, CNK

The top 10 open-market insider purchases and sales filed at the SEC Monday.

5 Health Care Stocks With Upside

These health care stocks are scheduled to report their quarterly earnings today.

10 Biotech Stocks Expected to at Least Double

The following 10 biotech stocks, though exceptionally risky, are expected to double, triple or quadruple in the next 12 months.

Stock Offerings: Kodiak Oil & Gas

Kodiak Oil & Gas announces the pricing of its public offering of 25 million shares.

NeurogesX Inc. Q1 2010 Earnings Call Transcript

NeurogesX Inc. Q1 2010 Earnings Call Transcript

Qutenza(R) (capsaicin) 8% Patch For Treatment Of Post-Shingles Pain Now Available

A single one-hour Qutenza localized treatment can provide three months relief from pain associated with postherpetic neuralgia

NeurogesX To Present At BioCentury Future Leaders In The Biotech Industry Conference

Scheduled to Ring NASDAQ Opening Bell on April 6, 2010

Earnings Roundup: Palm, Cintas

Earnings roundup: Palm's phone sales slump, Cintas profit slides as unemployment rose

NeurogesX Shares Rise Following FDA Approval

NeurogesX shares rise as Food and Drug Administration approves Qutenza pain patch

NeurogesX Gets FDA Approval For Pain Patch

NeurogesX receives Food and Drug Administration approval for Qutenza pain patch

CEO Sells $10.8M Worth of Guess

Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.

NeurogesX Names Board Member, Meets Nasdaq Rules

NeurogesX said it named Bradford Goodwin to board, regaining compliance with Nasdaq rules

NeurogesX, FDA Agree On Qutenza Study

NeurogesX to perform small, add-on study of Qutenza following agreement with FDA

Biotech Mailbag: NeurogesX Patchy at Best

It's not clear how this tiny biotech's pain patch can compete with a host of rivals, large and small.

Wednesday's Health Winners & Losers

Immtech's pneumonia drug is put on hold.

Tuesday's Health Winners & Losers

InterMune rises on an FDA approval.

Tuesday's Small-Cap Winners & Losers

NeurogesX pain relief patch gets investors' attention.

NeurogesX Climbs on Pain Patch Data

A study shows that its NGX-4010 reduced pain for eight weeks in patients with postherpetic neuralgia.

Tuesday's Health Winners & Losers

ImClone is falling.

Tuesday's Health Winners & Losers

Qiagen rises on a licensing deal with Germany's Epigenomics.